Anika reported third-quarter revenue of $30.6 million, up 10%, and gross margin of 62%, raising 2026 revenue growth guidance to 6% to 10%. HylaFast’s PMA was deemed not approvable, while Integrity revenue grew more than 30% year over year.
ANIK · Anika Therapeutics, Inc.
One customer — 49% of revenue (nine-months ended September 30, 2026)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
One customer — 47% of revenue (three-months ended September 30, 2026)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
One customer — 51% of revenue (three-months ended September 30, 2025)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
One customer — 50% of revenue (nine-months ended September 30, 2025)
“Revenue from the Company’s sole significant customer, DePuy Synthes, formerly Johnson & Johnson MedTech, as a percentage of the Company’s total revenue was 47% and 51% for the three-months ended September 30, 2026, and 2025, respectively, and 49% and 50% for the nine-months ended September 30, 2026, and 2025, respectively.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Anika Therapeutics reported revenue of 30,594 thousand U.S. dollars and a net loss of 311 thousand U.S. dollars for the three months ended September 30, 2026.
Anika Therapeutics reported third-quarter revenue of $30.6 million, up 10% year over year, raised 2026 revenue guidance to 6% to 10% and adjusted EBITDA margin guidance to 15% to 17%, while receiving FDA notice that Hyalofast PMA application was not approvable.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 6, 2026TL;DR. Anika reported 10% third-quarter revenue growth, improved profitability, $45.0 million of cash, expanded Integrity adoption, increased manufacturing output, advanced Cingal, secured improved Hyvisc economics and reintroduced Hyalomatrix, while raising the lower ends of several 2026 guidance ranges. Risks include the non-approvable Hyalofast PMA, lower Commercial Channel guidance, reduced operating cash flow, sequential gross-margin pressure and modest 2027 growth guidance that includes expected pricing declines.
- + Integrity revenue increased more than 30% year over year and 37% year to date, with adoption expanding into foot, ankle and knee applications.
- + Manufacturing output expanded, with cross-link-line volumes more than 50% above 2022 levels and further capacity growth planned.
- + Cingal bioequivalence enrollment was completed early, and the NDA is expected before year-end 2027.
- − The FDA found the Hyalofast PMA application not approvable based primarily on its submitted clinical data.
- − Nine-month operating cash flow fell to $2.8 million from $6.6 million because of inventory and capacity investments.
- − Gross margin declined sequentially from 65% in the second quarter to 62% in the third quarter.
- − The 2027 outlook provides only flat-to-5% total company revenue growth and includes expected U.S. OA pricing declines and flat-to-modestly-lower OEM revenue.
- − The fourth-quarter commercial outlook is not expected to recover the summer softness in U.S. elective surgical procedures.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted income (loss) from continuing operations per share non-GAAP | $1.18 | For the Nine Months Ended September 30, 2026 | — |
| Adjusted EBITDA non-GAAP | 16.48M | For the Nine Months Ended September 30, 2026 | — |
| Adjusted net income (loss) from continuing operations non-GAAP | 15.89M | For the Nine Months Ended September 30, 2026 | — |
| Commercial Channel revenue | $14M | third quarter of 2026 | — |
| Commercial Channel revenue growth | 17% | third quarter of 2026 | — |
| Integrity revenue | $7.5M | trailing 12 months | — |
| Integrity revenue growth | 37% | year to date | — |
| OEM Channel revenue | $16.6M | third quarter of 2026 | +4.8% |
|
|
|||
| OEM Channel revenue growth | 5% | third quarter of 2026 | — |
| Regenerative Solutions revenue growth | 12% | third quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANIK
this stock
Anika Therapeutics, Inc.
|
$182.44M | +41.7% | -5.9% | — | 2.4% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$67.96B | +36.4% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$51.90B | +7.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.28B | +35.3% | +4.3% | 96.0 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANIK | -2.4% | -33.9% | -6.3% | -35.0% | +41.7% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +1.5% | -28.3% | -2.8% | -31.6% | +34.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.